Expert Interview
A Second Look at Pliant Therapeutics' bexotegrast and the updated data from the INTEGRIS-PSC Phase 2a trial in primary sclerosing cholangitis (PSC) and biliary fibrosis
Ticker(s): PLRXInstitution: Rush University Medical Center
- Professor of Internal Medicine, Chair of Hepatology, & Associate Director of Solid Organ Transplantation,at Rush University Medical Center.
- Research interests focus on viral hepatitis – from both a drug development and a clinical perspective - liver transplantation, and complications of chronic liver disease.
- Author of the AASLD/IDSA hepatitis C guidance document; Co-chair of the National ALF Medical Advisory Committee and is currently a member of the steering committee for the hepatitis C special interest group for the AASLD.
Reflecting on the INTEGRIS-PSC Phase 2a trial, can you elaborate on the safety profile of PLN-74809 observed over the 12-week period, especially concerning its tolerability in patients with suspected moderate to severe liver fibrosis?
Added By: sara_adminHow does the observed reduction in liver fibrosis markers ELF and PRO-C3 with PLN-74809 administration contribute to our understanding of its antifibrotic efficacy in PSC patients?
Added By: sara_adminBased on MRI imaging results from the trial, can you discuss the implications of improved hepatocyte function and bile flow in patients treated with PLN-74809?
Added By: sara_adminIn comparison with existing treatment options for PSC, where does PLN-74809 stand in terms of effectiveness and patient outcomes, particularly in light of the trial results?
Added By: sara_adminThe trial noted a significant reduction in itch severity with PLN-74809. How important is this finding for the overall quality of life and symptom management in PSC patients?
Added By: sara_adminConsidering the varied dosages tested in the trial, how might PLN-74809 enable more personalized treatment strategies for PSC patients?
Added By: sara_adminWith the ongoing trial set to continue for a 24-week period, what are your expectations regarding the long-term efficacy and safety of PLN-74809 in PSC treatment?
Added By: sara_adminFollowing these promising trial results, what are the anticipated next steps in the clinical development and regulatory process for PLN-74809, and how might this influence its accessibility to patients?
Added By: sara_adminHow does the use of single nuclei RNA sequencing (snRNA-seq) combined with the precision-cut liver slice (PCLivS) platform enhance our understanding of bexotegrast’s cell-specific effects in treating biliary fibrosis?
The study indicates that bexotegrast had an attenuated effect on immune cell gene expression compared to ALK5i. What are the potential clinical implications of this finding for patients with PSC?
Added By: sara_adminCan you discuss the specific response profiles of key pathologic cell types, such as myofibroblasts and cholangiocytes, to bexotegrast treatment? How does this compare to their response to ALK5i?
Added By: sara_adminWhat were the most significant differentially expressed genes (DEGs) and pathways identified in the study for bexotegrast-treated cells, and how do these contribute to its antifibrotic effects?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
